| GSK Pays CureVac $328M in mRNA Vaccines Pact—Excluding COVID-19 | Frank Vinluan | 07/20/20 | Europe |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Mallinckrodt’s Kidney Failure Drug Narrowly Wins Backing of FDA Panel | Frank Vinluan | 07/16/20 | Europe |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Sarah de Crescenzo | 07/09/20 | Boston |
| BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity | Frank Vinluan | 07/01/20 | Europe |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal | Sarah de Crescenzo | 06/10/20 | National |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| NodThera Adds $55M to Advance Drugs to Better Regulate Inflammation | Sarah de Crescenzo | 06/03/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| New Webinars: In Vitro Hepatotoxicity Assessment Solutions & Enzyme Fragment Complementation Tech | Editors | 05/27/20 | Boston |
| Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq | Frank Vinluan | 05/22/20 | National |
| Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More | Frank Vinluan | 05/22/20 | National |
| ADC’s $233M IPO Brings It to NYSE With Cancer Drug Launch on Horizon | Frank Vinluan | 05/15/20 | New York |
| Genfit Contender in Heated NASH Drug Race Fails in Phase 3 Study | Sarah de Crescenzo | 05/11/20 | National |
| Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More | Frank Vinluan | 05/08/20 | National |
| Encouraging Signals for New Cancer Cell Therapy Strategies | Mandy Jackson | 05/06/20 | National |
| Bio Roundup: Remdesivir Data, Erasca’s $200M, a New FDA Nod & More | Sarah de Crescenzo | 05/01/20 | National |
| ADC Therapeutics Resubmits IPO to Fuel Cancer Drug Filing, Launch Plans | Frank Vinluan | 04/27/20 | New York |
